Chen JJ, Sahel JA, Biousse V, et al. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology. 2016;123(9):1999-2003. doi:https://doi.org/10.1016/j.ophtha.2016.05.006
Kobayashi D, Suyama Y, Osugi Y, Arioka H, Takahashi O, Kuriyama N. Incidence of cardiovascular events in polymyalgia rheumatica and giant cell arteritis amongst an Asian population: propensity score matched cohort study. Int J Rheum Dis. 2018;21(6):1314-1321. doi:https://doi.org/10.1111/1756-185X.13328
Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi:https://doi.org/10.1002/art.41774
Nordborg E. Epidemiology of biopsy-positive giant cell arteritis: an overview. Clin Exp Rheumatol. 2000;18(4 suppl 20):S15-S17.
Pearce JM. Sir Jonathan Hutchinson (1828-1913) and an early description of temporal arteritis. J Neurol Neurosurg Psychiatry. 1994;57(2):216. doi:https://doi.org/10.1136/jnnp.57.2.216
Pradeep S, Smith JH. Giant cell arteritis: practical pearls and updates. Curr Pain Headache Rep. 2018;22(1):1. doi:https://doi.org/10.1007/s11916-018-0655-y
Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004;18(5):705-722. doi:https://doi.org/10.1016/j.berh.2004.06.003
Spiera RF. Polymyalgia rheumatica and temporal arteritis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Elsevier; 2020:chap 271.
Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32(3):259-265. doi:https://doi.org/10.1097/WNO.0b013e318268aa9b



